LAG3: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: LAG3

NCBI ID: G3902

LAG3

LAG3: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

LAG3 (long non-coding RNA-gene 3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. LAG3 is a key regulator of gene expression and has been shown to play a role in the regulation of immune and inflammatory responses, as well as cell survival and metabolism.

The LAG3 gene was first identified in the genomic database by researchers at the University of California, San Francisco in 2011. The gene is located on the X chromosome and has a length of approximately 230 nucleotides. LAG3 is expressed in nearly all human tissues and has has been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and survival.

One of the key functions of LAG3 is its role in the regulation of gene expression. LAG3 has been shown to interact with various transcription factors, including T-cell factor (TGF-β), to promote the expression of target genes. This interaction between LAG3 and TGF-β have been shown to play a role in the regulation of cellular processes such as cell growth, differentiation, and survival.

In addition to its role in gene expression, LAG3 has also been shown to play a role in the regulation of DNA replication and repair. LAG3 has been shown to interact with the protein component TAU, which is involved in the regulation of DNA replication and repair. This interaction between LAG3 and TAU has been shown to contribute to the regulation of cellular processes such as DNA replication, error repair, and cell survival.

The potential drug target status of LAG3 is based on its involvement in the regulation of cellular processes that are often targeted by drugs for various diseases, including cancer. LAG3 has been shown to be involved in the regulation of cell adhesion, which is a process that is often targeted by drugs for diseases such as cancer. LAG3 has also been shown to be involved in the regulation of cell migration, which is a process that is often targeted by drugs for diseases such as cancer.

In addition to its potential as a drug target, LAG3 has also been shown to be a potential biomarker for various diseases, including cancer. LAG3 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. This suggests that LAG3 may be a useful biomarker for the diagnosis and treatment of these diseases.

In conclusion, LAG3 is a non-coding RNA molecule that has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and survival. Its potential drug target status and its involvement in the regulation of cellular processes make it an attractive target for research and development of new treatments for various diseases, including cancer. Further research is needed to fully understand the role of LAG3 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Lymphocyte Activating 3

Functions: Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185)

The "LAG3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LAG3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets